Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer

[1] Berchuck A(1990)Overexpression of Her-2/Neu is associated with poor survival in advanced epithelial ovarian-cancer Cancer Res 50 4087-91

[2] Kamel A(1996)The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer Br J Cancer 73 301-6

[3] Whitaker R(2007)HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients PLoS One 2 e1138-21

[4] Kerns B(2009)Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab Clin Cancer Res 15 2010-32

[5] Olt G(2011)Treatment of HER2-positive breast cancer: current status and future perspectives Nat Rev Clin Oncol 9 16-31

[6] Kinney R(2015)A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE Future Oncol 11 3113-84

[7] Bartlett JM(2006)Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients Breast Cancer Res Treat 98 179-48

[8] Langdon SP(2012)Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 938-19

[9] Simpson BJ(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-61

[10] Stewart M(2011)Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies Clin Cancer Res 17 4451-6

[1] Berchuck A(1990)Overexpression of Her-2/Neu is associated with poor survival in advanced epithelial ovarian-cancer Cancer Res 50 4087-91

[2] Kamel A(1996)The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer Br J Cancer 73 301-6

[3] Whitaker R(2007)HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients PLoS One 2 e1138-21

[4] Kerns B(2009)Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab Clin Cancer Res 15 2010-32

[5] Olt G(2011)Treatment of HER2-positive breast cancer: current status and future perspectives Nat Rev Clin Oncol 9 16-31

[6] Kinney R(2015)A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE Future Oncol 11 3113-84

[7] Bartlett JM(2006)Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients Breast Cancer Res Treat 98 179-48

[8] Langdon SP(2012)Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 938-19

[9] Simpson BJ(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-61

[10] Stewart M(2011)Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies Clin Cancer Res 17 4451-6